Neoplasms,Colorectal clinical trials at UCSF
1 in progress, 0 open to eligible people
Sorry, not currently recruiting here
GSK-3β is a potentially important therapeutic target in human malignancies. The Actuate 1801 Phase 1/2 study is designed to evaluate the safety and efficacy of 9-ING-41, a potent GSK-3β inhibitor, as a single agent and in combination with cytotoxic agents, in patients with refractory cancers.
San Francisco, California and other locations
Our lead scientists for Neoplasms,Colorectal research studies include Pamela Munster.